Nelotanserin

DB12555InvestigationalSmall molecule

Nelotanserin has been used in trials studying the treatment of Lewy Body Dementia, Visual Hallucinations, Dementia With Lewy Bodies, and REM Sleep Behavior Disorder. It is a highly selective antagonist... It increases non-REM sleep, the most restorative phase of the sleep cycle, without sacrificing REM or dream sleep.

Mechanism: Nelotanserin potently and selectively targets the 5-HT2A serotonin receptor, blocking a stimulatory pathway of the central nervous system. This mechanism is not expected to have the side effects of the GABA-A treatments.
Curator reviewed
Formula / weight: C₁₈H₁₅BrF₂N₄O₂ · 437.245 g/mol (avg)
Code names: APD-125

Resolves to

Compound

UNII4ZA73QEW2PCAS839713-36-9ChEMBLCHEMBL598172PubChem11683556

Structure

InChIKeyCOSPVUFTLGQDQL-UHFFFAOYSA-NSMILESCOC1=CC=C(NC(=O)NC2=CC=C(F)C=C2F)C=C1C1=C(Br)C=NN1C

Targets

P28223HTR2A

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Nelotanserin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account